company background image
506879 logo

Gujarat Themis Biosyn BSE:506879 Stock Report

Last Price

₹466.60

Market Cap

₹33.9b

7D

-4.8%

1Y

200.6%

Updated

20 Jul, 2024

Data

Company Financials

Gujarat Themis Biosyn Limited

BSE:506879 Stock Report

Market Cap: ₹33.9b

506879 Stock Overview

Engages in the manufacture of pharmaceuticals and medicinal chemicals in India.

506879 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends1/6

Gujarat Themis Biosyn Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gujarat Themis Biosyn
Historical stock prices
Current Share Price₹466.60
52 Week High₹530.00
52 Week Low₹152.22
Beta-0.16
11 Month Change-7.74%
3 Month Change20.94%
1 Year Change200.57%
33 Year Change448.55%
5 Year Change6,163.09%
Change since IPO77,666.67%

Recent News & Updates

Recent updates

Shareholder Returns

506879IN PharmaceuticalsIN Market
7D-4.8%-0.8%-1.3%
1Y200.6%46.4%43.0%

Return vs Industry: 506879 exceeded the Indian Pharmaceuticals industry which returned 46.3% over the past year.

Return vs Market: 506879 exceeded the Indian Market which returned 43% over the past year.

Price Volatility

Is 506879's price volatile compared to industry and market?
506879 volatility
506879 Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement6.4%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.2%

Stable Share Price: 506879 has not had significant price volatility in the past 3 months.

Volatility Over Time: 506879's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1981159Guha Guhathakuratawww.gtbl.in

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin.

Gujarat Themis Biosyn Limited Fundamentals Summary

How do Gujarat Themis Biosyn's earnings and revenue compare to its market cap?
506879 fundamental statistics
Market cap₹33.90b
Earnings (TTM)₹591.63m
Revenue (TTM)₹1.70b

57.3x

P/E Ratio

20.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
506879 income statement (TTM)
Revenue₹1.70b
Cost of Revenue₹687.40m
Gross Profit₹1.01b
Other Expenses₹419.19m
Earnings₹591.63m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 26, 2024

Earnings per share (EPS)8.14
Gross Margin59.52%
Net Profit Margin34.84%
Debt/Equity Ratio0%

How did 506879 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

12%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.